Ingen internetforbindelse — viser den gemte version af siden.

ABBOTT LABORATORI…

USUSD
← Til Screeneren

ABBOTT LABORATORIES (XETRA:ABL) — Biotechnology: Pharmaceutical Preparations. Antal børser, hvor selskabets aktier handles: 4. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.

Om Virksomheden

Websted
abbott.com
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Hovedkontor
North Chicago, United States
Administrerende Direktør
Robert Ford
Ansatte
73 000
Grundlagt
1888
Børsnoteret Siden
20.12.2007 (XETRA:ABL)
Udestående Aktier
1.73 mia. pr. 2026-06-30
Free Float
1.72 mia.
Markedsværdi
169.83 mia. USD
Insidere
0.49%
Institutionelle Investorer
81.79%
Branche (SIC)
Pharmaceutical Preparations
Juridisk Form
AZUK
ISIN
US0028241000
LEI
HQD377W2YR662HK5JX27
P/E
33.4
Udbetalingsgrad
66.7%
FCF
7.38 mia. USD
Udbetaling / FCF
57%
Gæld
34.0 mia. USD
3.7 år FCF
Udbyttestreak
43 år
Indtjening, FCF og udbetalt udbytte — for de 12 måneder frem til 31.03.2026 (selskabets seneste rapport).
NAV
29.89 USD · P/NAV 3.42
Balancedato31.03.2026
Aktiver110 mia. USD
− Forpligtelser57.7 mia. USD
= Total Egenkapital52.7 mia. USD
− Ikke-Kontrollerende Interesser640 mio. USD
= NAV (aktiekapital i selskabets aktionærer)52.1 mia. USD
− Goodwill35.2 mia. USD
− Immaterielle Aktiver17.9 mia. USD
= Materiel NAV−1.04 mia. USD
Aktier1 741 812 429
NAV pr. Aktie29.89 USD
Håndgribelig NAV pr. Aktie−0.59 USD
Aktiekurs (ABL)88.8600 EUR
P/NAV3.42
NAV-Historie
BalancedatoNAVNAV pr. Aktie
31.03.202652.1 mia. USD29.89 USD
31.12.202552.1 mia. USD30.00 USD
30.09.202551.0 mia. USD29.30 USD
30.06.202550.6 mia. USD29.05 USD
31.03.202548.8 mia. USD28.05 USD
31.12.202447.7 mia. USD27.48 USD
30.09.202439.8 mia. USD22.94 USD
30.06.202439.3 mia. USD22.60 USD
Beskrivelse

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

annonce

Børser og Tickere

BørsTickerValutaPrisType
US USA StocksABT primærUSD104.89 +0.20%almindelige aktier
LSE London Stock Exchange0Q15 IOBUSD103.27 +4.07%almindelige aktier
MX Mexican Stock ExchangeABT sekundærMXN1 935.4 +2.40%almindelige aktier
XETRA XetraABL sekundærEUR88.86 +2.21%almindelige aktier

Kurs over 3 Måneder

stigningsdag faldsdag udbyttets ex-dato udbetalingsdatoHold musen over / tryk på en dag — åbnings-, luknings-, højeste og laveste kurs

Udbytte

Pr. År, XETRA:ABL: 1.6798 EUR (3 udb.)

ABBOTT LABORATORIES (ABL) udbetaler udbytte kvartalsvis. Pr. År (12 måneder op til og med den senest annoncerede betaling): 1.6798 EUR pr. Aktie (betalinger: 3). Det svarer til cirka 1.89% af den nuværende aktiekurs. Baseret på betalingshistorikken forventes næste ex-udbyttedato omkring 13.01.2027. Uafbrudt udbyttehistorik: 43 år.

Ex-DatoUdbetalingBeløb%TypeTicker
2026-07-15—0.5599 EUR0.7/2.8 %kvartalsvisXETRA:ABL
2026-04-15—0.5599 EUR0.6/2.5 %kvartalsvisXETRA:ABL
2026-01-15—0.5599 EUR0.5/2.0 %kvartalsvisXETRA:ABL
2025-10-15—0.5244 EUR0.5/1.8 %kvartalsvisXETRA:ABL
2025-07-15—0.5244 EUR0.5/1.8 %kvartalsvisXETRA:ABL
2025-04-15—0.5244 EUR0.5/1.8 %kvartalsvisXETRA:ABL
2025-01-15—0.5244 EUR0.5/1.8 %kvartalsvisXETRA:ABL
2024-10-15—0.4888 EUR0.5/1.8 %kvartalsvisXETRA:ABL
2024-07-15—0.4888 EUR0.5/2.0 %kvartalsvisXETRA:ABL
2024-04-12—0.4888 EUR0.5/1.8 %kvartalsvisXETRA:ABL
2024-01-11—0.4888 EUR0.5/1.8 %kvartalsvisXETRA:ABL
2023-10-12—0.4533 EUR0.5/2.0 %kvartalsvisXETRA:ABL
2023-07-13—0.4533 EUR0.5/1.8 %kvartalsvisXETRA:ABL
2023-04-13—0.4533 EUR0.5/1.9 %kvartalsvisXETRA:ABL
2023-01-12—0.4533 EUR0.4/1.6 %kvartalsvisXETRA:ABL
2022-10-13—0.4177 EUR0.4/1.6 %kvartalsvisXETRA:ABL
2022-07-14—0.4177 EUR0.4/1.2 %kvartalsvisXETRA:ABL
2022-04-13—0.4177 EUR0.4/0.8 %kvartalsvisXETRA:ABL
2022-01-13—0.4177 EUR0.4/0.4 %kvartalsvisXETRA:ABL

Nyheder Denne Uge

Pressemeddelelser fra virksomhedens investorhjemmeside, opdateret dagligt. Links fører til virksomhedens hjemmeside. Overskrifterne er på originalsproget, som på virksomhedens hjemmeside.

Største Ejere

EjerAndelAktierRapportdato
BlackRock8.82%152.56 mio.2026-06-30
Vanguard Capital Managem…6.57%113.75 mio.2026-06-30
State Street Corporation4.68%80.93 mio.2026-06-30
Charles Schwab Investmen…3.45%59.67 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…3.2%55.3 mio.2026-06-30
Vanguard Portfolio Manag…2.83%49.02 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…2.61%45.14 mio.2026-06-30
Geode Capital Management…2.27%39.22 mio.2026-06-30
Capital Research Global…2.13%36.91 mio.2026-06-30
Capital International In…2%34.65 mio.2026-06-30
SCHWAB STRATEGIC TRUST-S…1.9%32.82 mio.2026-05-31
Morgan Stanley1.54%26.61 mio.2026-06-30
NORGES BANK1.35%23.35 mio.2026-06-30
iShares Trust-iShares Co…1.34%23.2 mio.2026-08-31
Fidelity Concord Street…1.3%22.52 mio.2026-07-31
SPDR S&P 500 ETF TRUST-S…1.23%21.31 mio.2026-08-31
WASHINGTON MUTUAL INVEST…1.01%17.53 mio.2026-07-31
VANGUARD INDEX FUNDS-Van…0.96%16.58 mio.2026-06-30
SELECT SECTOR SPDR TRT-S…0.72%12.52 mio.2026-08-31
Investment Co of America0.6%10.33 mio.2026-06-30
STARKS DANIEL J (Directo…≈0.39%6.75 mio.2026-04-27
FORD ROBERT B. (Chief Ex…≈0.03%522 6642026-08-25
ALLEN HUBERT L. (Officer…≈0.01%200 2812025-02-25
SALVADORI DANIEL GESUA S…≈0.01%146 3772026-03-02
CONROY KEVIN T (Director…≈0.01%133 7372026-04-24
MORELAND MARY K (Officer…≈0.01%116 1362026-03-02
EARNHARDT LISA D (Office…≈0.01%98 9842026-02-24
SCOGGINS CHRISTOPHER J (…≈0%82 1232026-02-24
WAINER ANDREA F (Officer…≈0%74 3812025-03-03
The Vanguard Group———
BOUDREAU PHILIP P (Chief…——2026-04-23